CDKN2B-AS1 and cancer: It has been proven that ANRIL is implicated in several malignant tumors, and high expression of ANRIL is associated with aggressive clinicopathologic features, such as high histological grade tumor size, advanced tumor–node–metastasis stage, and poor overall survival with the disease (211–213).